Lucid Diagnostics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUCD research report →
Range $2 – $2
Price Chart
About the company
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma.
- CEO
- Lishan Aklog
- IPO
- 2021
- Employees
- 82
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on LUCD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $72.57M
- P/E
- -0.93
- PEG
- -0.01
- P/S
- 13.35
- P/B
- 12.00
- EV/EBITDA
- -1.53
- Div Yield
- 0.00%
- Gross Margin
- -20.58%
- Op Margin
- -941.73%
- Net Margin
- -892.75%
- ROE
- -610.65%
- ROIC
- -209.68%
Latest fiscal year · YoY change
- Revenue
- $4.71M+8.3%
- Gross Profit
- $-2,836,000+27.7%
- Op Income
- $-49,640,000
- Net Income
- $-58,010,000-27.4%
- EPS
- $-0.69+34.3%
- OCF Growth
- -5.3%
- FCF Growth
- -4.2%
- 52W High
- $1.63
- 52W Low
- $0.30
- 50D MA
- $0.56
- 200D MA
- $0.96
- Beta
- 1.16
- RSI (14)
- 39
- Avg Volume
- 5.15M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lucid said Medicare is now paying for EsoGuard through Novitas, triggering an immediate commercial push and early October volume momentum.· November 12, 2026
- Medicare began paying for EsoGuard claims from Lucid’s Texas lab, which management called the company’s most important commercial breakthrough to date.
- Q3 revenue was $1.2 million on 2,870 tests sold, roughly flat year over year; non-GAAP net loss per share was $0.06.
- October was a record month for test volume at more than 1,800 tests, and management said Novitas payments have been consistent since mid-October.
- Cash was $18 million at quarter end, rising to about $33 million pro forma after the $15 million Series C preferred financing.
- Management expects a strong Q4, with Medicare coverage, new payer wins, and updated guidelines all supporting the commercial case.
Third-quarter revenue was $1.2 million, essentially flat with last year’s third quarter, on 2,870 tests sold with a billable value of about $7.9 million. Non-GAAP net loss per share was $0.06, unchanged from the prior quarter, and GAAP loss per share was $0.03 versus $0.08 last quarter, aided by a noncash fair-value gain. Total operating expenses were $13.5 million, down about 6% sequentially, and non-GAAP operating expenses were $11.8 million versus $12.3 million. Cash at September 30 was $18 million; after the October 21 $15 million Series C preferred offering, pro forma cash was about $33 million. For Q4, management said October test volume was a record month at more than 1,800 tests, Medicare claims are being paid consistently by Novitas, and the company expects Q4 revenue dynamics to begin changing materially as Medicare reimbursement scales.
Lishan Aklog framed Medicare reimbursement as a seminal turning point, saying Lucid has entered a new chapter focused on commercial acceleration and revenue growth. He emphasized that the Texas lab’s Novitas pathway is independent of the pending MolDx LCD and allows the company to move immediately rather than waiting for broader LCD finalization. His tone was upbeat and operationally focused, with repeated references to early momentum, a strong October, and the ability to scale without current capacity constraints.
Dennis McGrath highlighted a balance-sheet improvement from $18 million in cash at quarter end to about $33 million pro forma after the $15 million Series C preferred financing. He said burn in Q3 was $10.2 million, the lowest of the last four quarters, versus an average burn of $11.6 million over the last four quarters including cash interest. He noted Q3 revenue of $1.2 million on 2,870 tests, average revenue per test of $419, and an average insurance allowable amount of $1,700 per successful claim, up about 19% from $1,420 in Q2. He also said every Medicare claim allowed to date has been paid at the full $1,940 rate, and described the company’s margin profile as highly scalable, with the next patient contributing about 90% margin.
Analysts focused on how quickly the record October volume could translate into revenue, and management said it was too early to extrapolate but that Q4 should be solid. Questions also centered on whether the Novitas route differs from MolDx, whether old rejected claims could be resubmitted, and whether Medicare payment would affect salesforce expansion. Management said the Novitas pathway is separate from MolDx, that prior tests performed in other lab jurisdictions depend on the LCD process, and that sales hiring will remain measured until the new revenue trajectory is clearer. On commercialization, management said the entire regular sales team is now oriented toward Medicare-age patients, with additional creative outreach efforts available beyond the core field force.
The bull case is that Lucid finally has a paid Medicare pathway for EsoGuard, and management said Novitas payments are already consistent and at full rate. If October’s record volume and the early Medicare mix persist, revenue could improve quickly without a near-term need for major capacity or cost expansion. Management also cited supportive payer and guideline developments, including Concert coverage progress and AGA draft guidelines naming EsoGuard and EsoCheck as a high-certainty alternative to endoscopy.
The biggest risk is execution: management itself said it is too early to extrapolate October’s 1,800-test pace, especially with Q4 seasonality and year-end holidays. Revenue recognition is still partly constrained by collection timing and non-Medicare claims remain less predictable, while the MolDx LCD is still delayed and not yet finalized. The company also remains loss-making, with $10.2 million of quarterly burn and a large share count dilution profile following the Series C financing and convertible debt structure.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.2%
- Shares Outstanding
- 194.71M
- Float Shares
- 144.52M
of shares held by institutions
118 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alyeska Investment Group, L.P. | 8.86M | ▲ 8.86M |
| Blackrock, Inc. | 8.39M | ▲ 14.76K |
| Vanguard Capital Management LLC | 6.05M | ▼ 511.12K |
| Vanguard Group Inc | 4.97M | ▲ 444.61K |
| Aberdeen Group PLC | 4.42M | ▲ 596.94K |
| Masters Capital Management LLC | 4.00M | 0 |
| Geode Capital Management, LLC | 3.57M | ▼ 223.94K |
| State Street Corp | 2.44M | ▲ 4.88K |
| First Manhattan Co. LLC. | 2.19M | ▲ 1.87M |
| Wells Fargo & Company/Mn | 2.07M | ▲ 792.66K |
| Northern Trust Corp | 1.22M | ▲ 549.29K |
| Ubs Group AG | 1.14M | ▲ 299.64K |
Held by 88 ETFs
Biggest fund positions in LUCD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | Matheis Dennis | buy | 245,000 |
| Mar 23, 26 | Lee Victoria Tou-ho | other | 0 |
| Mar 23, 26 | Lee Victoria Tou-ho | other | 0 |
| Mar 23, 26 | Lee Victoria Tou-ho | other | 0 |
| Feb 20, 26 | Aklog Lishan | other | 2,170,000 |
| Feb 20, 26 | Matheis Dennis | other | 123,000 |
| Feb 20, 26 | White Debra | other | 123,000 |
| Feb 20, 26 | Sparks Ronald M | other | 123,000 |
| Feb 20, 26 | SOKOLOV JACQUE J | other | 123,000 |
| Feb 20, 26 | PALUMBO JOHN R | other | 123,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LUCD coverage
Recent articles, reports, and earnings notes.
No research on LUCD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LUCD report →PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
prnewswire.com · Nov 13
What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 12
Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 5
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
prnewswire.com · Nov 5
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.